Day: June 3, 2021

IDEX Biometrics: Employee Share Purchase Plan - 3 June 2021

IDEX Biometrics: Employee Share Purchase Plan – 3 June 2021

The board of directors of IDEX Biometrics ASA has resolved to issue 972,642 ordinary shares at NOK 2.08 per share to employees who participate in the company’s Employee Share Purchase Plan (ESPP), which plan was approved by the annual general meeting on 15 May 2020. 54 employees participated in the ESPP in this period. The participating employees have elected to invest a part of the base salary in ordinary shares in the company. Purchase takes place every three months. The shares are restricted for three months. Following the issue, the Company’s share capital will be NOK 137,734,306.50 divided into 918,228,710 shares each with a nominal value of NOK 0.15. Primary insidersIDEX discloses transactions by the following primary insiders in IDEX shares ISIN NO0003070609:–   CEO Vince Graziani acquired 19,984 ordinary shares at...

Continue reading

Grant of Incentive Subscription Rights in IDEX Biometrics 3 June 2021

Grant of Incentive Subscription Rights in IDEX Biometrics 3 June 2021

The board of directors of IDEX Biometrics ASA resolved on 3 June 2021 to issue 2,000,000 incentive subscription rights to an officer in the IDEX group. The grant was made under the company’s 2021 incentive subscription rights plan as resolved at the annual general meeting on 12 May 2021. The exercise price of the subscription rights is NOK 2.38 per share. The subscription rights vest by 25% per year over four years and expire on 12 May 2026. Following the grant there are 62,053,609 subscription rights outstanding in IDEX. Primary insiderCatharina Eklof, Chief Commercial Officer of IDEX Biometrics ASA, received on 3 June 2021 a grant of 2,000,000 incentive subscription rights to shares in IDEX. The grant was made for no consideration. IDEX shares have ISIN NO0003070609. For further information contact:Marianne Bøe, Investor Relations...

Continue reading

Celestica Provides Highlights from Its Capital Equipment Virtual Roundtable and Confirmatory Business Update

Celestica Provides Highlights from Its Capital Equipment Virtual Roundtable and Confirmatory Business Update

TORONTO, June 03, 2021 (GLOBE NEWSWIRE) — Celestica Inc. (NYSE: CLS)(TSX: CLS), a leader in design, manufacturing and supply chain solutions for the world’s most innovative companies, hosted an analyst and investor virtual roundtable on its Capital Equipment business and provided a confirmatory business update, today after market close. During the virtual meeting, Celestica’s management provided participants with an in-depth overview of its Capital Equipment business, reaffirmed its Q2 2021 guidance in the context of recent developments in the market (further to its press release of May 26, 2021 announcing the virtual roundtable), and conducted a Q&A with analysts. Speakers were CEO Rob Mionis, CFO Mandeep Chawla and Vice President, Capital Equipment, Gregory Marvell. Below is a summary of the highlights of the discussion...

Continue reading

Quantum Materials Shareholder Update

Quantum Materials Shareholder Update

San Marcos, TX, June 03, 2021 (GLOBE NEWSWIRE) — Quantum Materials Corp (QTMM) (“Quantum” or the “Company”), a leading American nanomaterial and cadmium free quantum dot producer and product company, is issuing this release to provide shareholder and investors with information regarding the Company and in light of the 10 trading day order of suspension issued by the Securities and Exchange Commission (the “Commission”) on May 12, 2021 due to a lack of current information as a result of the failure to file certain periodic reports under the Company’s reporting obligations with the Commission. The trading halt, which commenced at 9:30am on May 13, 2021 and terminated at 11:59pm on May 26, 2021, has resulted in the Company’s shares no longer being quoted or traded on the Pink Tier operated by the OTC Markets Group, Inc. At this time,...

Continue reading

Diversified Royalty Corp. Announces June 2021 Cash Dividend and Annual General Meeting Details

Diversified Royalty Corp. Announces June 2021 Cash Dividend and Annual General Meeting Details

VANCOUVER, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) — Diversified Royalty Corp. (TSX: DIV and DIV.DB) (the “Corporation” or “DIV”) is pleased to announce that its board of directors has approved a cash dividend of $0.01667 per common share for the period of June 1, 2021 to June 30, 2021, which is equal to $0.20 per common share on an annualized basis. The dividend will be paid on June 30, 2021 to shareholders of record as of the close of business on June 15, 2021. Annual General Meeting The Corporation will be holding its Annual General Meeting of shareholders at 9:00 am (Pacific time) on Monday, June 28, 2021 (the “Meeting”). In order to ensure the safety of our shareholders, colleagues, stakeholders and the community at large and to comply with physical distancing recommendations and mandates of public health authorities...

Continue reading

Class Acceleration Corp. Receives NYSE Notice Regarding Delayed Form 10-Q Filing

Class Acceleration Corp. Receives NYSE Notice Regarding Delayed Form 10-Q Filing

WOODSIDE, Calif., June 03, 2021 (GLOBE NEWSWIRE) — Class Acceleration Corp. (NYSE: CLAS, CLAS.U, CLAS.W) (the “Company”) today announced that it received a notice from the New York Stock Exchange (the “NYSE”) indicating that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (the “Q1 2021 Form 10-Q”) with the Securities and Exchange Commission (the “SEC”). The notice has no immediate effect on the listing of the Company’s stock on the NYSE. The NYSE informed the Company that, under the NYSE’s rules, the Company can regain compliance with the NYSE’s continued listing requirements by filing the Q1 2021 Form 10-Q with the SEC at any...

Continue reading

Xenon Pharmaceuticals Provides Corporate Update Following its Annual Meeting of Shareholders

Xenon Pharmaceuticals Provides Corporate Update Following its Annual Meeting of Shareholders

BURNABY, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, provided a corporate update following its 2021 Annual Meeting of Shareholders (the “Annual Meeting”) held today on June 3, 2021. Dr. Simon Pimstone, Executive Chair of Xenon’s Board of Directors stated, “We announced plans for a leadership transition earlier in the year, implemented a seamless succession plan, and effected these appointments at our Annual Meeting. Ian Mortimer, who takes on the role of CEO and joins our board of directors, has worked alongside me for the past seven years and is ideally suited to lead Xenon, together with Sherry Aulin, who was appointed Xenon’s Chief Financial Officer. It has been a privilege to head up this talented executive team while serving Xenon’s...

Continue reading

LGI Homes Reports May 2021 Home Closings

LGI Homes Reports May 2021 Home Closings

THE WOODLANDS, Texas, June 03, 2021 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) today announced it closed 911 homes in May 2021, up from 640 homes closed in May 2020, representing year-over-year growth of 42.3%. The Company ended the first five months of 2021 with 4,420 home closings, a 43.5% increase over 3,080 home closings during the first five months of 2020. As of May 31, 2021, the Company had 104 active selling communities. About LGI Homes, Inc. Headquartered in The Woodlands, Texas, LGI Homes, Inc. engages in the design, construction and sale of homes in Texas, Arizona, Florida, Georgia, New Mexico, Colorado, North Carolina, South Carolina, Washington, Tennessee, Minnesota, Oklahoma, Alabama, California, Oregon, Nevada, West Virginia, Virginia and Pennsylvania. Since 2018, LGI Homes has been ranked as the 10th largest...

Continue reading

INDUS Announces Updates to Acquisition and Disposition Pipelines

INDUS Announces Updates to Acquisition and Disposition Pipelines

NEW YORK, June 03, 2021 (GLOBE NEWSWIRE) — INDUS Realty Trust, Inc. (Nasdaq: INDT) (“INDUS” or the “Company”) announced today that it recently entered into an agreement (the “Purchase Agreement”) to acquire, for a purchase price of $42.0 million, an approximately 50% leased, 395,000 square foot industrial/logistics building in Charlotte, North Carolina (the “Charlotte Acquisition”). Under the terms of the Purchase Agreement, INDUS expects to close on the Charlotte Acquisition by the end of the 2021 second quarter. Michael Gamzon, President and Chief Executive Officer of INDUS, commented, “We are very excited by this opportunity to expand our presence in the Charlotte market. This acquisition complements our existing portfolio and development pipeline and offers additional upside as we pursue leasing opportunities for the balance...

Continue reading

Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

– In pivotal Phase 3 JUPITER-02 study, toripalimab plus chemotherapy significantly improved PFS compared to chemotherapy alone in high and low PD-L1 expression subgroups – –  Although median overall survival (OS) analysis was not yet mature, a 40% reduction in risk of death was observed in the toripalimab arm compared to placebo – – Data to be presented June 6, 2021 at ASCO plenary session – – Over 30 toripalimab abstracts in more than 10 tumor types published at ASCO 2021 – SHANGHAI, China, and REDWOOD CITY, Calif., June 03, 2021 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced positive results from the pivotal study “JUPITER-02”, a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating...

Continue reading